This week the world lost a friend, colleague and advocate for IBD patients. For decades, Patrick McLean dedicated his talents to advancing research into anti-mycobacterial treatment solutions for chronic immune diseases such as Crohn’s and multiple sclerosis. He had great compassion for patients, and exemplified the best of humanity. Our community was blessed to have known him, and he leaves a legacy that will ripple throughout time.

Human Para’s second research, which sought to detect MAP in blinded blood samples from Crohn’s and control pediatric subjects, has now concluded. Read on to see the results.

Human Paratuberculosis Foundation is dedicated to providing the latest research and information about the role of Mycobacterium avium subsp. paratuberculosis (MAP) in chronic immune conditions such as Crohn’s disease, multiple sclerosis, Type 1 diabetes, ulcerative colitis, sarcoidosis, Parkinson’s disease, rheumatoid arthritis, lupus and more. Our goal is to assist researchers, health care professionals and patients around the world. We are grateful for the support of our community and look forward to taking this journey together. Enjoy the latest edition of our quarterly newsletter!

What is the Susceptibility of MAP Strains to Antibiotic Combinations? Human Para, in conjunction with the Keating Family Foundation, is proud to announce their commitment to support a new research partnership between Johns Hopkins Medicine and Otakaro Pathways. Read on to learn more about our latest project!

Human Para is excited to share the preprint article detailing the results of our landmark MAP/Crohn’s disease testing study that began in 2018. Viable MAP was detected in a significant number of study subjects across all groups. A more detailed analysis is available on the HumanPara.org website. Thank you to all of the participants and their families, the researchers who volunteered their time for this study, and the donors who made funding this critical research a reality.

Human Paratuberculosis Foundation is dedicated to providing the latest research and information about the role of Mycobacterium avium subsp. paratuberculosis (MAP) in chronic immune conditions such as Crohn’s disease, multiple sclerosis, Type 1 diabetes, ulcerative colitis, sarcoidosis, Parkinson’s disease, rheumatoid arthritis, lupus and more. Our goal is to assist researchers, health care professionals and patients around the world. We are grateful for the support of our community and look forward to taking this journey together. Enjoy the latest edition of our quarterly newsletter!

Bacteriophage (phage) are viruses that target specific bacteria, and are among the most numerous bio-entities on earth. They have recently reemerged as an alternative to antibiotic therapy in resistant disease. While phage experts have historically agreed that phages cannot be used to target intracellular bacteria like MAP, a new biotechnology company has been formed to do just that. MAP/PATH, LLC’s mission is to control and eliminate diseased caused by Mycobacterium avium spp paratuberculosis, or MAP. See what they have discovered and learn about their innovative solutions to the problem of MAP contamination in food products.

Dr. Horacio Bach and his research team have published a new paper where they report the infection of human dendritic cells by Mycobacterium avium spp. paratuberculosis (MAP).

Dendritic cells are found in the immune system and act as messengers between the innate and adaptive immune systems. They capture antigens from foreign invaders and present them to the T cells, which initiate the immune response. They also work with B cells to maintain immune memory.

As dendritic cells are migratory, these findings may represent a way to explain the dissemination of MAP in the body and the pathogenesis of other chronic diseases associated with MAP.

No, life ain’t always beautiful Tears will fall sometimes Life ain’t always beautiful But it’s a beautiful ride.

What’s it like to walk a mile in a Crohn’s patient’s shoes? These compelling interviews provide a window into the battles patients and parents face on the road to healing; including Anti-MAP, surgery and hope for a cure. Thank you to the brave men and women who chose to share these stories with Human Para.